Citius Pharmaceuticals (NASDAQ:CTXR) Stock Attempts To Rebound After The News

November 6, 2021

Shares of Citius Pharmaceuticals (NASDAQ:CTXR) moved higher in the previous trading. Will the stock continue to move higher? Trading Data On Friday, CTXR stock ended flat at $1.9500 with more than 980.51K shares, compared to its average volume of 2.47 million shares. The stock has moved within a range of $1.9100 – 1.9800 after opening the trade at $1.9250. Expands Management Team Late-stage biopharmaceutical company dedicated to the development and…

Read More >>

Citius Pharmaceuticals Inc. (CTXR) Stock Surges 13% in a Month: What Next?

September 8, 2021

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is up 13% in a month. The company has signed a definitive agreement with Dr. Reddy’s Laboratory Ltd (NYSE:RDY) subsidiary Dr. Reddy’s Laboratories SA to acquire an exclusive license for E7777 (denileukin diftitox). E7777 is late-stage cancer immunotherapy for CTCL treatment. It is an engineered IL-W diphtheria toxin fusion antigen that is an enhanced ONTAK formulation that previously received FDA approval to treat recurrent or persistent…

Read More >>

Citius Pharmaceuticals Inc (NASDAQ:CTXR) Stock Continues to Trend Lower: Now What?

August 16, 2021

The biopharmaceutical firm Citius Pharmaceuticals Inc (NASDAQ:CTXR) was in focus among many investors on Friday after the company announced its financial results for the third fiscal quarter of the year for the period ended on June 30, 2021. The stock ended the day with gains of 2% and it is likely to be in focus among many investors today as well. In this situation, it might be a good idea…

Read More >>